(“QVC Group”) (Nasdaq: QVCGA, QVCGB, QVCGP) today reported fourth quarter and year end 2024 results (1). “2024 was an ...
Year-over-year growth in bookings and backlog; book-to-bill ratio of approximately 1.1x for FY'24 and 1.3x for Q4'24Record ...
Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback